Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines

Current Infectious Disease Reports

Volumn 15, Issue 2, 2013, Pages 184-190

  Muñoz Almagro, Carmen ^a   Navarro Torne, Adoracion ^b   Pallares, Roman ^c  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Clinical implications; Epidemiologic; Second generation pneumococcal conjugate vaccines

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANOREXIA; ANTIBIOTIC RESISTANCE; COMMUNITY ACQUIRED PNEUMONIA; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEVER; HAEMOPHILUS INFLUENZAE; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; NONHUMAN; PNEUMOCOCCAL INFECTION; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84877921705     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0326-4     Document Type: Review

References (71)

1. Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect. 2010;61(2):114-24. A good review and meta-analyisis including 63 original articles involving 3,408 meningitis survivors during the years 1991-2009.
2. O'Brien KL, Wolfson LJ, Watt JP, et al. Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893-902. A country-specific review about the incidence of invasive disease and deaths in children younger than 5 years performed by the HIB and pneumococcal global burden of disease study team.
3. McEllistrem MC, Adams JM, Patel K, et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2005;40:1738-44.
4. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86:408-16.
5. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642-50.
6. Hausdorff P, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet. 2005;5:83-93.
7. Centers for Disease Control and Prevention (CDC). Recommendations of the immunization practices advisory committee (ACIP) update: pneumococcal polysaccharide vaccine usage - United States. MMWR Morb Mortal Wkly Rep. 1984;33:273-6.
8. de Roux A, Schmöle-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46(7):1015-23.
9. Black S, Shinefield H, Fireman B. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187-95.
10. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810-5.
11. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10-6.
12. Pilishvili T, Lexau C, Farley MM, et al. Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
13. Rückinger S, van der Linden M, Reinert RR, et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27(31):4136-41.
14. Hanquet G, Lernout T, Vergison A, et al. Belgian IPD Scientific Committee. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine. 2011;29(16):2856-64.
15. Ingels H, Rasmussen J, Andersen PH, et al. Danish Pneumococcal Surveillance Collaboration Group 2009-2010. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine. 2012;30(26):3944-50.
16. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784-92.
17. Muñoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174-82.
18. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298(15):1772-8.
19. Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30:122-40.
20. de Sevilla MF, García-García JJ, Esteva C, et al. Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine. Pediatr Infect Dis J. 2012;31(2):124-8.
21. Obando I, Muñoz-Almagro C, Arroyo LA, et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis. 2008;14(9):1390-7.
22. Thomas MF, Sheppard CL, Guiver M, et al. Emergence of pneumococcal 19A empyema in UK children. Arch Dis Child.2012. Oct 16. Epub ahead of print.
23. Strachan RE, Cornelius A, Gilbert GL, et al. Australian Research Network in Empyema. Bacterial causes of empyema in children, Australia, 2007-2009. Emerg Infect Dis. 2011;17(10):1839-45.
24. Byington CL, Hulten KG, Ampofo K, et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin Microbiol. 2010;48(2):520-5.
25. WHO Publication. Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine. 2012;30(32):4717-8.
26. Chowdhury P, Balluz L, Town M, et al. Surveillance of certain health behaviors and conditions among states and selected local areas - Behavioral Risk Factor Surveillance System, United States, 2007. MMWR Surveill Summ. 2010;59:1-220.
27. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955-60.
28. Nuorti JP, Whitney CG. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1-18.
29. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics. 2010;126(1):186-90.
30. Scientific committee on vaccine preventable diseases Hong Kong. Recommendations on the use of 13-valent pneumococcal conjugate vaccine in the children immunization program. Accessed 20 October 2012 http://www.chp.gov.hk/ files/pdf/briefing-for-hcw-by-dr-cbchow.pdf.
31. Centers for Disease Control and Prevention (CDC). Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-9.
32. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17(6):1017-26.
33. Vanderkooi OG, Scheifele DW, Girgenti D, et al. Canadian PCV13 Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31(1):72-7.
34. Martinón-Torres F, Gimenez-Sanchez F, Gurtman A, et al. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. Pediatr Infect Dis J. 2012;31(4):392-9.
35. Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines. 2011;10(7):951-80.
36. Bryant-Genevier M, Khoie T, Lee L, Vaillancourt J. FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee. Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Accesed 20 October 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ BloodVaccinesandOtherBiologics/ VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM239495.pdf.
37. Pneumococcal vaccine support. Accessed 19 October 2012 http://www.gavialliance.org/support/nvs/pneumococcal/.
38. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/ vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf Accessed December 17, 2012.
39. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10).
40. Singleton R, Wenger J, Klejka JA, et al. The 13-Valent Pneumococcal Conjugate Vaccine for Invasive Pneumococcal Disease in Alaska Native Children: Results of a Clinical Trial. Pediatr Infect Dis J. 2012 Sep 20. Epub ahead of print. A prelicensure open-label clinical trial in Alaskan native children to assess effectiveness of PCV-13 in reducing PCV13-caused IPD. Concomitant reduction of non-PCV-related IPD was also observed.
41. Moore M, Link-Gelles R, Farley M, et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, United States, 2010-11. Presented at 8th International Symposium on Pneumococci & Pneumococcal Diseases. March 13, 2012.
42. Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634-43.
43. Strutton DR, Farkouh RA, Rubin JL, et al. Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data. BMC Infect Dis. 2012;12:175. doi: 10.1186/1471-2334-12-175.
44. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127-31. A case control evaluation of effectiveness of PCV13-specific serotypes in children performed in the U.K. after 1 year of introduction of PCV13 in the national immunization schedule.
45. Hak E, Grobbee DE, Sanders EAM, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66(9):378-83.
46. Weycker D, Sato R, Strutton D, et al. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine. 2012;30(36):5437-44. A microsimulation model of costs of IPD and all-cause nonbacteraemic pneumonia in adults conducted in the U.S.
47. Kuhlmann A, Theidel U, Pletz MW, et al. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev. 2012;2:4.
48. Benito-Fernandez J, Raso SM, Pocheville-Gurutzeta I, et al. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque country of Spain. Pediatr Infect Dis J. 2007;26:667-71.
49. Herz AM, Greenhow TL, Alcantara J, et al. Changing epidemiology of outpatient bacteremia in 3- to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr Infect Dis J. 2006;25:293-300.
50. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139-46.
51. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244-56.
52. Spencer DA, Close AJ, Simmister C, et al. Impact of the 13-valent pneumococcal vaccine on the incidence of paediatric empyema in the north of England. In: Abstracts book of the 29th Annual Meeting of the European Society of Paediatric Infectious Diseases. The Hague, Netherlands, June 7-11, 2011; abstr. no 637.
53. Taylor S, Marchisio P, Vergison A, et al. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis. 2012;54(12):1765-73.
54. Xu Q, Almudervar A, Casey JR, et al. Nasopharyngeal bacterial interactions in children. Emerg Infect Dis. 2012;18(11):1738-45.
55. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29(4):304-9.
56. van Gils EJM, Hak E, Veenhoven RH, et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One. 2011;6:e20229. A randomised controlled trial on the effect of PCV7 on pneumococcal carriage and nasopharyngeal colonisation of S. aureus (secondary outcome) in healthy newborns up to 2 years of age before the implementation of PCV7 in the Dutch national immunisation programme.
57. Dukers-Muijrers NHTM, Stobberingh E, Beissert P et al. Nasal carriage of Streptococcus pneumoniae serotypes and Staphylococcus aureus in Streptococcus pneumoniae-vaccinated and non-vaccinated young children. Epidemiol Infect. 2012. Available on CJO 2012 doi: 10.1017/S095026881200115X.
58. Moore DP, Dagan R, Madhi SA. Respiratory viral and pneumococcal coinfection of the respiratory tract: implications of pneumococcal vaccination. Expert Rev Respir Med. 2012;6(4):451-65.
59. Launes C, de-Sevilla MF, Selva L, et al. Viral coinfection in children less than five years old with invasive pneumococcal disease. Pediatr Infect Dis J. 2012;31(6):650-3.
60. Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205(3):401-11.
61. Yildirim I, Stevenson A, Hsu KK, et al. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods. Pediatr Infect Dis J. 2012;31(10):1016-21.
62. Muñoz-Almagro C, Ciruela P, Esteva C, et al. Catalan study group of invasive pneumococcal disease. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J Infect. 2011;63(2):151-62.
63. Gladstone RA, Jefferies JM, Faust SN, et al. Continued control of pneumococcal disease in the UK- the impact of vaccination. J Med Microbiol. 2011;60:1-8.
64. Healthy people 2020. 2020 topics and objectives. Immunization and infectious diseases Available at http://www.healthypeople.gov/2020/ topicsobjectives2020/overview.aspx?topicid=23 Accesed 27 october 2012.
65. Wilby KJ, Werry D. A review of the effect of immunization programs on antimicrobial utilization. Vaccine. 2012;30:6509-14.
66. Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children with acute otitis media (AOM). In: Abstracts book of the 51st Interscience Congress on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2011; abstr. no. G3-1709.
67. Sá-Leão R, Nunes S, Brito-Avo A, et al. Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clin Microbiol Infect. 2009;15:1002-7.
68. Fleming-Dutra K, Mbaeyi C, Link-Gelles R, et al. Streptococcus pneumoniae Serotype 15A in Psychiatric Unit, Rhode Island, US, 2010-2011. Emerg Infect Dis. 2012;18(11):1889-93.
69. Gladstone RA, Jefferies JM, Faust SN, et al. Pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Rev Vaccines. 2012;11(8):889-902.
70. van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One. 2012;7(7):339150. A study of serotype-specific differences in clinical presentation of IPD, outcome, and impact in the quality of life in the context of the 7-, 10-, and 13-valent pneumococcal conjugate vaccines, using an electronic linked database in the U.K.
71. Principi N, Esposito S. Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza. Hum Vaccin. 2011;7:905-12.